Despite the increase in DRD disease burden, current pharmacologic approaches are limited to laser therapy and intravitreally injected anti-vascular endothelial growth factor (VEGF) agents due largely to our limited understanding of DRD pathophysiology [6,7,8,9]. The gene discussed is VEGFA; the disease is dystonia 5.